• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于含有单体近红外荧光蛋白作为报告分子的 SARS-CoV-2 假病毒的实时高通量中和试验。

A real-time and high-throughput neutralization test based on SARS-CoV-2 pseudovirus containing monomeric infrared fluorescent protein as reporter.

机构信息

Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, USA.

Pacific Center for Emerging Infectious Diseases, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI, USA.

出版信息

Emerg Microbes Infect. 2021 Dec;10(1):894-904. doi: 10.1080/22221751.2021.1925163.

DOI:10.1080/22221751.2021.1925163
PMID:33929934
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8143625/
Abstract

Neutralizing antibodies to SARS-CoV-2 have been shown to correlate with protection in animals and humans, disease severity, survival, and vaccine efficacy. With the ongoing large-scale vaccination in different countries and continuous surge of new variants of global concerns, a convenient, cost-effective and high-throughput neutralization test is urgently needed. Conventional SARS-CoV-2 neutralization test is tedious, time-consuming and requires a biosafety level 3 laboratory. Despite recent reports of neutralizations using different pseudoviruses with a luciferase or green fluorescent protein reporter, the laborious steps, inter-assay variability or high background limit their high-throughput potential. In this study we generated lentivirus-based pseudoviruses containing a monomeric infrared fluorescent protein reporter to develop neutralization assays. Similar tropism, infection kinetics and mechanism of entry through receptor-mediated endocytosis were found in the three pseudoviruses generated. Compared with pseudovirus D614, pseudovirus with D614G mutation had decreased shedding and higher density of S1 protein present on particles. The 50% neutralization titers to pseudoviruses D614 or D614G correlated with the plaque reduction neutralization titers to live SARS-CoV-2. The turn-around time of 48-72 h, minimal autofluorescence, one-step image quantification, expandable to 384-well, sequential readouts and dual quantifications by flow cytometry support its high-throughput and versatile applications at a non-reference and biosafety level 2 laboratory, in particular for assessing the neutralization sensitivity of new variants by sera from natural infection or different vaccinations during our fight against the pandemic.

摘要

针对严重急性呼吸系统综合征冠状病毒 2 型(SARS-CoV-2)的中和抗体已被证实与动物和人类的保护作用、疾病严重程度、存活率和疫苗功效相关。目前,不同国家正在大规模接种疫苗,全球关注的新变种不断涌现,因此迫切需要一种方便、具有成本效益且高通量的中和检测方法。传统的 SARS-CoV-2 中和检测方法繁琐、耗时,且需要生物安全 3 级实验室。尽管最近有报道称使用带有荧光素酶或绿色荧光蛋白报告基因的不同假病毒进行中和检测,但繁琐的步骤、检测内变异性或高背景限制了其高通量检测的潜力。在本研究中,我们构建了基于慢病毒的假病毒,其包含单体近红外荧光蛋白报告基因,以开发中和检测方法。我们发现三种假病毒具有相似的趋向性、感染动力学和通过受体介导的内吞作用进入细胞的机制。与假病毒 D614 相比,含有 D614G 突变的假病毒脱落减少,且表面 S1 蛋白密度更高。假病毒 D614 或 D614G 的 50%中和效价与活 SARS-CoV-2 的蚀斑减少中和效价相关。48-72 小时的检测周转时间、最小自发荧光、一步式图像定量、可扩展至 384 孔板、连续读取和通过流式细胞术进行双重定量,支持其在非参考和生物安全 2 级实验室中的高通量和多功能应用,特别是在评估新变体的中和敏感性方面,可用于评估自然感染或不同疫苗接种后的血清中和敏感性,以帮助我们抗击这一大流行病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20ba/8143625/2e6e50631b7a/TEMI_A_1925163_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20ba/8143625/4e77ed877a17/TEMI_A_1925163_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20ba/8143625/fbe75ef0a606/TEMI_A_1925163_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20ba/8143625/88687ee00a6c/TEMI_A_1925163_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20ba/8143625/2e6e50631b7a/TEMI_A_1925163_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20ba/8143625/4e77ed877a17/TEMI_A_1925163_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20ba/8143625/fbe75ef0a606/TEMI_A_1925163_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20ba/8143625/88687ee00a6c/TEMI_A_1925163_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20ba/8143625/2e6e50631b7a/TEMI_A_1925163_F0004_OC.jpg

相似文献

1
A real-time and high-throughput neutralization test based on SARS-CoV-2 pseudovirus containing monomeric infrared fluorescent protein as reporter.基于含有单体近红外荧光蛋白作为报告分子的 SARS-CoV-2 假病毒的实时高通量中和试验。
Emerg Microbes Infect. 2021 Dec;10(1):894-904. doi: 10.1080/22221751.2021.1925163.
2
Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals.快速灵活的平台,用于评估抗 SARS-CoV-2 抗体中和作用和刺突蛋白特异性抗病毒药物。
mSphere. 2021 Aug 25;6(4):e0057121. doi: 10.1128/mSphere.00571-21. Epub 2021 Jul 28.
3
Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells.基于携带 SARS-CoV-2 S 蛋白的水疱性口炎病毒(VSV)假病毒和过表达 ACE2 的 BHK21 细胞的稳健中和测定法。
Emerg Microbes Infect. 2020 Dec;9(1):2105-2113. doi: 10.1080/22221751.2020.1815589.
4
Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions.用 SARS-CoV-1 和 SARS-CoV-2 刺突假型鼠白血病病毒颗粒进行中和测定。
Virol J. 2021 Jan 4;18(1):1. doi: 10.1186/s12985-020-01472-1.
5
Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays.评估针对 SARS-CoV-2 的体液免疫:蚀斑减少中和试验的验证和常规及替代中和测定法的多实验室比较。
Microbiol Spectr. 2021 Dec 22;9(3):e0088621. doi: 10.1128/Spectrum.00886-21. Epub 2021 Nov 17.
6
Neutralizing Antibody Responses to SARS-CoV-2 in Recovered COVID-19 Patients Are Variable and Correlate With Disease Severity and Receptor-Binding Domain Recognition.恢复期 COVID-19 患者对 SARS-CoV-2 的中和抗体反应具有变异性,与疾病严重程度和受体结合域识别相关。
Front Immunol. 2022 Jan 31;13:830710. doi: 10.3389/fimmu.2022.830710. eCollection 2022.
7
Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays.基于细胞和替代 SARS-CoV-2 中和测定的评估。
J Clin Microbiol. 2021 Sep 20;59(10):e0052721. doi: 10.1128/JCM.00527-21. Epub 2021 Jul 21.
8
Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants.开发针对包含奥密克戎的 SARS-CoV-2 变异株的假病毒中和测定法。
Viruses. 2022 Jun 18;14(6):1332. doi: 10.3390/v14061332.
9
Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency.通过结合具有高效力的糖基化 RBD 构象表位来中和 SARS-CoV-2 及其关注的变异株 Alpha、Beta、Gamma 和 Delta 的鼠源单克隆抗体的分离和鉴定。
Front Immunol. 2021 Oct 26;12:750386. doi: 10.3389/fimmu.2021.750386. eCollection 2021.
10
Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.利用具有 SARS-CoV-2 刺突蛋白的水疱性口炎病毒评估 SARS-CoV-2 中和抗体。
Virol J. 2021 Jan 12;18(1):16. doi: 10.1186/s12985-021-01490-7.

引用本文的文献

1
Retrovirus-based pseudotyped virus neutralisation assays overestimate neutralising activity in sera from participants receiving integrase inhibitors.基于逆转录病毒的假型病毒中和试验高估了接受整合酶抑制剂的参与者血清中的中和活性。
Sci Rep. 2025 Aug 5;15(1):28580. doi: 10.1038/s41598-025-11362-7.
2
Evolution of the PRNT: Merging tradition and innovation to set the gold standard in the era of automation.血浆中和试验(PRNT)的演变:融合传统与创新,在自动化时代树立黄金标准。
Hum Vaccin Immunother. 2025 Dec;21(1):2528368. doi: 10.1080/21645515.2025.2528368. Epub 2025 Jul 9.
3
Chikungunya virus antepartum transmission and abnormal infant outcomes in a cohort of pregnant women in Nigeria.

本文引用的文献

1
Sixteen novel lineages of SARS-CoV-2 in South Africa.南非出现 16 种新型 SARS-CoV-2 谱系。
Nat Med. 2021 Mar;27(3):440-446. doi: 10.1038/s41591-021-01255-3. Epub 2021 Feb 2.
2
Changes in the humoral immunity response in SARS-CoV-2 convalescent patients over 8 months.8个月内新冠康复患者体液免疫反应的变化。
Cell Mol Immunol. 2021 Feb;18(2):490-491. doi: 10.1038/s41423-020-00605-4. Epub 2021 Jan 8.
3
Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK.英国 SARS-CoV-2 疫情的建立和谱系动态。
尼日利亚孕妇队列中寨卡病毒的产前传播和婴儿异常结局。
Int J Infect Dis. 2024 Feb;139:92-100. doi: 10.1016/j.ijid.2023.11.036. Epub 2023 Dec 4.
4
Determining the Time of Booster Dose Based on the Half-Life and Neutralization Titers against SARS-CoV-2 Variants of Concern in Fully Vaccinated Individuals.根据完全接种疫苗者对 SARS-CoV-2 关注变异株的半衰期和中和滴度来确定加强针的接种时间。
Microbiol Spectr. 2023 Aug 17;11(4):e0408122. doi: 10.1128/spectrum.04081-22. Epub 2023 Jul 10.
5
Identification of severe acute respiratory syndrome coronavirus 2 breakthrough infections by anti-nucleocapsid antibody among fully vaccinated non-healthcare workers during the transition from the delta to omicron wave.在从德尔塔毒株流行期过渡到奥密克戎毒株流行期期间,通过抗核衣壳抗体在完全接种疫苗的非医护人员中识别严重急性呼吸综合征冠状病毒2突破性感染情况。
Front Med (Lausanne). 2022 Nov 29;9:1019490. doi: 10.3389/fmed.2022.1019490. eCollection 2022.
6
Genomic analysis of SARS-CoV-2 variants of concern circulating in Hawai'i to facilitate public-health policies.对在夏威夷流行的关注的 SARS-CoV-2 变体进行基因组分析,以促进公共卫生政策。
PLoS One. 2022 Dec 1;17(12):e0278287. doi: 10.1371/journal.pone.0278287. eCollection 2022.
7
Baculovirus-Free SARS-CoV-2 Virus-like Particle Production in Insect Cells for Rapid Neutralization Assessment.昆虫细胞中无杆状病毒的 SARS-CoV-2 病毒样颗粒生产用于快速中和评估。
Viruses. 2022 Sep 20;14(10):2087. doi: 10.3390/v14102087.
8
Dynamic SARS-CoV-2 emergence algorithm for rationally-designed logical next-generation vaccines.用于合理设计逻辑下一代疫苗的 SARS-CoV-2 动态出现算法。
Commun Biol. 2022 Oct 10;5(1):1081. doi: 10.1038/s42003-022-04030-3.
9
COVID-19 vaccination and booster induced authentic-virus neutralizing antibody response is superior to SARS-CoV-2 natural infection induced response.新冠病毒疫苗接种及加强针诱导的真实病毒中和抗体反应优于新冠病毒自然感染诱导的反应。
J Clin Virol. 2022 Jul;152:105185. doi: 10.1016/j.jcv.2022.105185. Epub 2022 May 14.
10
Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model.在非人类灵长类动物免疫原性模型中,第三次加强免疫后的泛 SARS 中和反应。
Vaccine. 2022 Feb 23;40(9):1289-1298. doi: 10.1016/j.vaccine.2022.01.021. Epub 2022 Jan 31.
Science. 2021 Feb 12;371(6530):708-712. doi: 10.1126/science.abf2946. Epub 2021 Jan 8.
4
COVID-19-neutralizing antibodies predict disease severity and survival.COVID-19 中和抗体可预测疾病严重程度和存活率。
Cell. 2021 Jan 21;184(2):476-488.e11. doi: 10.1016/j.cell.2020.12.015. Epub 2020 Dec 15.
5
D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization.D614G 刺突突变增加了 SARS-CoV-2 对中和作用的敏感性。
Cell Host Microbe. 2021 Jan 13;29(1):23-31.e4. doi: 10.1016/j.chom.2020.11.012. Epub 2020 Dec 1.
6
SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity.SARS-CoV-2 刺突蛋白 D614G 突变增加了病毒粒子刺突密度和感染力。
Nat Commun. 2020 Nov 26;11(1):6013. doi: 10.1038/s41467-020-19808-4.
7
Coronavirus biology and replication: implications for SARS-CoV-2.冠状病毒的生物学与复制:对 SARS-CoV-2 的启示。
Nat Rev Microbiol. 2021 Mar;19(3):155-170. doi: 10.1038/s41579-020-00468-6. Epub 2020 Oct 28.
8
Neutralizing Antibody Responses in COVID-19 Convalescent Sera.新型冠状病毒感染恢复期患者血清中的中和抗体反应。
J Infect Dis. 2021 Jan 4;223(1):47-55. doi: 10.1093/infdis/jiaa673.
9
Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate.中和抗体与高感染率渔业船舶暴发期间人类免受 SARS-CoV-2 感染相关。
J Clin Microbiol. 2020 Oct 21;58(11). doi: 10.1128/JCM.02107-20.
10
A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction.一种基于抗体介导的 ACE2-刺突蛋白-蛋白相互作用阻断的 SARS-CoV-2 假病毒中和试验。
Nat Biotechnol. 2020 Sep;38(9):1073-1078. doi: 10.1038/s41587-020-0631-z. Epub 2020 Jul 23.